Compare YUM & ALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YUM | ALC |
|---|---|---|
| Founded | 1997 | 1945 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Restaurants | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.6B | 39.0B |
| IPO Year | 1997 | N/A |
| Metric | YUM | ALC |
|---|---|---|
| Price | $159.68 | $80.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 12 |
| Target Price | ★ $166.82 | $88.29 |
| AVG Volume (30 Days) | ★ 2.3M | 1.8M |
| Earning Date | 02-04-2026 | 02-24-2026 |
| Dividend Yield | ★ 1.87% | 0.27% |
| EPS Growth | ★ 6.32 | N/A |
| EPS | ★ 5.55 | 2.10 |
| Revenue | $8,214,000,000.00 | ★ $10,185,000,000.00 |
| Revenue This Year | $10.18 | $5.76 |
| Revenue Next Year | $6.29 | $7.24 |
| P/E Ratio | ★ $28.93 | $36.65 |
| Revenue Growth | ★ 8.81 | 4.34 |
| 52 Week Low | $137.33 | $71.55 |
| 52 Week High | $165.32 | $99.20 |
| Indicator | YUM | ALC |
|---|---|---|
| Relative Strength Index (RSI) | 56.10 | 53.79 |
| Support Level | $157.24 | $77.95 |
| Resistance Level | $165.32 | $80.77 |
| Average True Range (ATR) | 3.60 | 1.42 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 54.75 | 71.69 |
As of the end of 2024, Yum Brands generated over $65 billion in systemwide sales from more than 61,000 restaurants across 155 markets, making it the world's second-largest restaurant firm by dollar sales. Its portfolio includes KFC (31,981 stores), Pizza Hut (20,225), Taco Bell (8,757), and Habit Burger (383), with 70% of locations in international markets. As 98% of its portfolio is franchised, Yum's business model is tilted toward recurring franchise royalties and marketing contributions (66% of revenue), with the balance derived from sales at company-owned locations. The company traces its roots to a 1997 spinoff of PepsiCo's restaurant assets.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.